Oncolyze
Oncolyze is a pre-clinical stage biopharmaceutical company dedicated to developing innovative cancer therapeutics. Their mission is to cure cancer by providing highly selective treatments that target and destroy cancer cells and stem cells, offering hope for potential cures. They focus on a unique mechanism of action involving fusion peptides that create pores in cancer cell membranes, leading to cell death through a process called 'pop-tosis'. Their lead candidate, OM-301, targets extracellular HDM2 on cancer cells, especially effective against AML, and is progressing through clinical development with plans for a Phase 1/2 trial. The company collaborates with top academic and medical institutions and aims to bring transformative treatments to cancer patients.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Lead investigational fusion peptide candidate for oncology
An investigational 32-amino-acid fusion peptide composed of a cell-surface binding element targeting extracellular HDM2 and an amphipathic membrane-active element that forms pores in the cancer cell membrane to induce rapid lytic cell death. Developed for acute myeloid leukemia (AML) and being evaluated for other hematologic and solid tumor indications.
Lead investigational fusion peptide candidate for oncology
An investigational 32-amino-acid fusion peptide composed of a cell-surface binding element targeting extracellular HDM2 and an amphipathic membrane-active element that forms pores in the cancer cell membrane to induce rapid lytic cell death. Developed for acute myeloid leukemia (AML) and being evaluated for other hematologic and solid tumor indications.
Services
Collaborative research agreements with academic cancer centers and translational institutes to evaluate peptide therapeutics in vitro and in vivo and to support translational study design.
Opportunities for licensing of peptide technology or partnering for development and commercialization of therapeutics exploiting the membrane‑disrupting mechanism.
Collaborative research agreements with academic cancer centers and translational institutes to evaluate peptide therapeutics in vitro and in vivo and to support translational study design.
Opportunities for licensing of peptide technology or partnering for development and commercialization of therapeutics exploiting the membrane‑disrupting mechanism.
Expertise Areas
- Peptide therapeutics development
- Targeted membrane-disrupting oncology agents
- Preclinical oncology and translational research
- In vitro and in vivo efficacy testing
Key Technologies
- Fusion peptide design and engineering
- Amphipathic membrane-active peptides
- Cell-surface target binding
- Flow cytometry